These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Jan 7, 2015ProNAi Initiates Phase II Trial of PNT2258 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- First Patient Dosed in the "Wolverine" Phase II Trial Evaluating ProNAi's BCL2 Targeting DNAi® Therapeutic PNT2258 - VANCOUVER, BC and PLYMOUTH, MI, Jan. 7, 2015 /CNW/ - ProNAi Therapeutics...
Dec 5, 2014ProNAi Reports Significant Activity and Ongoing Durable Responses in Relapsed or Refractory Non-Hodgkin's Lymphoma with PNT2258
- Updated results from pilot Phase II trial of the BCL2 targeting DNAi® therapeutic reported at ASH 2014 - VANCOUVER, BC and PLYMOUTH, MI, Dec. 5, 2014 /CNW/ - ProNAi Therapeutics Inc., a private...
Oct 22, 2014
ProNAi Therapeutics Inc., a private company dedicated to developing and commercializing a new class of therapies based on its proprietary DNAi® platform, today announced that it has added five...